Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Evofem Biosciences ( (EVFM) ) has issued an announcement.
Evofem Biosciences reported a 6% increase in net sales to $19.4 million for 2024, driven by the performance of Phexxi and the acquisition and relaunch of SOLOSEC. The company reduced its total operating expenses by 27% and improved its loss from operations by 57% compared to 2023. Additionally, Evofem entered into a merger agreement with Aditxt, Inc., and aims to reduce manufacturing costs through a partnership with Windtree Therapeutics. These strategic moves are expected to enhance profitability and expand market reach.
More about Evofem Biosciences
Evofem Biosciences, Inc. is a company focused on commercializing innovative products in women’s sexual and reproductive health. Their primary products include Phexxi, a hormone-free, on-demand contraceptive vaginal gel, and SOLOSEC, an oral antibiotic for treating bacterial vaginosis and trichomoniasis.
Average Trading Volume: 482,062
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1M
See more data about EVFM stock on TipRanks’ Stock Analysis page.